ArticleFrontiers in pharmacology2020

Identification of a Serotonin 2A Receptor Subtype of Schizophrenia Spectrum Disorders With Pimavanserin: The Sub-Sero Proof-of-Concept Trial Protocol.

Olga B Baltzersen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.